Defined by the absence of expression of endocrine receptors and lack of human epidermal growth factor receptor 2 (HER2) gene amplification, triple-negative breast cancer (TNBC) represents 15% to 20% of all breast cancers. Here, ERBB2 is linked to triple-negative breast carcinoma.